Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 6/20 | 0.35 |
| ▸ | SCD | O00767 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975814 | 0.83 | HCRTR1 (0.45) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL3974945 | 0.83 | HCRTR1 (0.54) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL5478785 | 0.82 | SMN1; SMN2 (0.48) | HCRTR1HCRTR2NPC1ALDH1A1RAB9A | |
| SCHEMBL4080514 | 0.81 | HCRTR1 (0.39) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL4080513 | 0.81 | HCRTR1 (0.39) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL2889901 | 0.80 | SMN1; SMN2 (0.48) | HCRTR1HCRTR2NPC1ALDH1A1LMNA | |
| SCHEMBL13878117 | 0.80 | HCRTR1 (0.38) | HCRTR1HCRTR2SCD5SCDNPC1 | |
| SCHEMBL2899332 | 0.80 | SMN1; SMN2 (0.48) | HCRTR1HCRTR2NPC1ALDH1A1LMNA | |
| SCHEMBL8066206 | 0.80 | USP30 (0.48) | HCRTR1HCRTR2ALDH1A1LMNAHTT | |
| SCHEMBL13412244 | 0.79 | HCRTR1 (0.51) | HCRTR1HCRTR2SCD5SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054793-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009054793-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111825-A1 | THIOPHENE 1,2,4-TRIAZOLE DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | HCRTR1 608/4885HCRTR2 347/4885SCD5 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.